The aim of this study was to evaluate the clinical efficacy and safety of sulfur hexafluoride (SF6) as a tamponading agent after donor placement during Descemet stripping endothelial keratoplasty (DSEK) surgery and to compare the outcomes with those of air.
Forty-four eyes of 44 consecutive patients who underwent DSEK were included in the study. Air was used in 22 eyes of 22 patients (air group), and SF6 was used in 22 eyes of 22 patients (SF6 group) to attach the donor lenticule. The complications, corrected visual acuity (CVA), and the endothelial cell density (ECD) results were compared between these 2 groups.
Six eyes had graft dislocation in the air group that underwent successful rebubbling on postoperative day 1. There was no graft dislocation in the SF6 group. There was no other complication observed in both the groups. The mean increase in the CVA was 1.09 ± 0.36 logarithm of the minimum angle of resolution in the air group, whereas it was 0.80 ± 0.57 logarithm of the minimum angle of resolution in the SF6 group. The mean increase in the CVA was not statistically different between the 2 groups (P = 0.060). Compared with the mean ECD in donor grafts, the mean decrease in the ECD was 222 ± 86 (44%) cells per square millimeter in the air group and 178 ± 52 (39%) cells per square millimeter in the SF6 group at the 1-year follow-up. The mean decrease in the ECD was statistically significantly higher in the air group compared with that in the SF6 group (P = 0.049).
SF6 is comparable to air for attaching the donor graft as a tamponading agent in DSEK surgery.
*Department of Ophthalmology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey; and
†Department of Ophthalmology, Istanbul Medipol University, School of Medicine, Istanbul, Turkey.
Reprints: Orkun Muftuoglu, Department of Ophthalmology, Istanbul Medipol University, School of Medicine, Medipol Mega Hospitals Complex, TEM Avrupa Otoyolu No 1, Bagcilar, Istanbul, Turkey (e-mail: firstname.lastname@example.org).
The authors have no funding or conflicts of interest to disclose.
Received June 18, 2013
Accepted November 04, 2013